Whether analyst are right or wrong is not the point...but you know that. Real Plll companies have analyst coverage with commercial projections. That's the whole point!
Do you really want to go there? Geron's stem cell program was canned due to politics but they at least always had their telomerase platform to fall back on, unlike some CEO's we know. Need I remind you the efforts Powers made to bring stem cell therapy to the next level, and she failed miserably.
Market Data 
Markets 
AI
